Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $38.30.

RCUS has been the subject of a number of recent research reports. Truist Financial reissued a “buy” rating and issued a $40.00 target price (up from $35.00) on shares of Arcus Biosciences in a report on Tuesday, September 8th. Wedbush boosted their target price on shares of Arcus Biosciences from $41.00 to $43.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a research note on Monday, August 10th. Lifesci Capital assumed coverage on Arcus Biosciences in a report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, Wells Fargo & Company increased their price target on Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Thursday, August 6th.

Arcus Biosciences Trading Up 0.2%

Shares of Arcus Biosciences stock opened at $25.30 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. Arcus Biosciences has a fifty-two week low of $12.11 and a fifty-two week high of $31.74. The company has a fifty day moving average of $28.40 and a 200 day moving average of $25.89. The company has a market capitalization of $3.22 billion, a P/E ratio of -6.49 and a beta of 0.81.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm’s revenue was down 74.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Arcus Biosciences will post -3.59 earnings per share for the current fiscal year.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, President Juan Jaen sold 20,067 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.62, for a total value of $574,317.54. Following the completion of the sale, the president owned 822,240 shares of the company’s stock, valued at $23,532,508.80. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,827 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,591 shares of company stock worth $2,744,492 over the last three months. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcus Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new position in Arcus Biosciences during the second quarter worth about $30,000. Hantz Financial Services Inc. increased its holdings in shares of Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after buying an additional 881 shares during the last quarter. KBC Group NV acquired a new stake in shares of Arcus Biosciences during the 1st quarter worth approximately $50,000. GAMMA Investing LLC raised its position in shares of Arcus Biosciences by 10.0% during the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock valued at $122,000 after buying an additional 359 shares during the period. Finally, Nykredit A S purchased a new stake in shares of Arcus Biosciences during the 2nd quarter valued at approximately $134,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines antibody-based therapies, small-molecule drugs and combination treatment strategies designed to influence the immune system and other biological pathways involved in tumor growth.

Its oncology pipeline includes investigational therapies targeting pathways such as TIGIT, PD-1, CD73, adenosine receptors and HIF-2?. Key programs have included domvanalimab, an anti-TIGIT antibody; zimberelimab, an anti-PD-1 antibody; quemliclustat, a CD73 inhibitor; etrumadenant, an adenosine receptor antagonist; and AB521, an HIF-2? inhibitor.